Showing posts with label Study. Show all posts
Showing posts with label Study. Show all posts

Wednesday, 3 November 2010

Tuesday, 2 November 2010

Largest-Yet Mesothelioma Study Shows Survival Benefit with New Drug

Largest-Yet Mesothelioma Study Shows Survival Benefit with New DrugPosted By Tony Vieira
June 4, 2006

Comments (0)

Largest-Yet Mesothelioma Study Shows Survival Benefit with New Drug

Key Words: chemotherapy, lung cancer, mesothelioma, pemetrexed. (Definitions of many terms related to cancer can be found in the Cancer.gov Dictionary.)

Researchers with the largest phase III trial to date for mesothelioma, an aggressive cancer affecting the lining of the lung, reported results showing that patients on a new chemotherapy drug regimen live longer and have less pain than those on an older drug. The findings were announced at the annual meeting of the American Society of Clinical Oncology meeting in Orlando, Fla., on May 20, 2002. (NOTE: The final data were subsequently published in the July 15, 2003, issue of the Journal of Clinical Oncology; see the journal abstract).

Pemetrexed (brand name Alimta

Case-Control Study of Cancer among US Army Veterans Exposed to Simian Virus 40-contaminated Adenovirus Vaccine

Case-Control Study of Cancer among US Army Veterans Exposed to Simian Virus 40-contaminated Adenovirus VaccinePosted By Tony Vieira
June 4, 2006

Comments (0)

Case-Control Study of Cancer among US Army Veterans Exposed to Simian Virus 40-contaminated Adenovirus Vaccine

Dana E. M. Rollison1, William F. Page2, Harriet Crawford2, Gloria Gridley3, Sholom Wacholder3, Jennifer Martin4, Richard Miller2 and Eric A. Engels3
1 Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
2 Medical Follow-up Agency, Institute of Medicine, the National Academies, Washington, DC.
3 Division of Cancer Epidemiology and Genetics, National Cancer Institute, Department of Health and Human Services, Rockville, MD.
4 RTI International, Rockville, MD.

Simian virus 40 (SV40) was an accidental contaminant of vaccines produced in monkey kidney tissue cultures in the 1950s and early 1960s, including a parenteral adenovirus vaccine given to several hundred thousand US military recruits. Detection of SV40 DNA in tumor tissues by some laboratories suggests that SV40 contributes to human cancers. To determine if entry into US Army service during periods of administration of SV40-contaminated adenovirus vaccine was associated with an increased risk of cancer, the authors conducted a case-control study of cancer occurring in male Army veterans who entered service in 1959-1961.

Cases of brain tumors (n